[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-338383-105":59,"doc-detail-338383-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","multi-omics-analysis-identifies-pttg1-as-a-prognostic-biomarker-associated-with-immunotherapy-and-chemotherapy-resistance","Multi-omics analysis identifies PTTG1 as a prognostic biomarker associated with immunotherapy and chemotherapy resistance","","Background: Pituitary tumor-transforming gene 1 (PTTG1) is important for tumor development, but its links to cancer prognosis, immunotherapy response, and medication sensitivity in pan-cancer settings require clarification. Methods: Public resources were used to evaluate gene and protein expression, prognosis, and genetic alteration patterns across 33 malignancies, and to assess relationships with tumor immunity and microenvironment, immunotherapy responsiveness, and anticancer drug sensitivity. Results: PTTG1 is overexpressed, predicts poor outcomes, and correlates with immune infiltration. High PTTG1 associates with immunotherapy resistance, T-cell exhaustion, cytotoxic T-lymphocyte dysfunction, and altered sensitivity to multiple drugs; siRNA knockdown reduces paclitaxel-resistant phenotypes. Conclusion: PTTG1 is proposed as a diagnostic and prognostic marker and a chemosensitivity and therapeutic target relevant to overcoming immunotherapy resistance.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/multi-omics-analysis-identifies-pttg1-as-a-prognostic-biomarker-associated-with-immunotherapy-and-chemotherapy-resistance/338383/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/multi-omics-analysis-identifies-pttg1-as-a-prognostic-biomarker-associated-with-immunotherapy-and-chemotherapy-resistance/338383.png","ImageObject",300,407,{"name":92,"@type":93},"Skyler","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-25","2026-09-21",true,{"@type":102,"interactionType":103,"userInteractionCount":39},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What is the research focus regarding PTTG1 in this study?","Question",{"text":112,"@type":113},"The study examines how PTTG1 relates to tumor prognosis, immunotherapy response, and medication sensitivity across pan-cancer datasets.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"Which analytical resources and approaches were used to study PTTG1?",{"text":117,"@type":113},"The work uses TIMER, GEPIA, Human Protein Atlas, TISCH2, cBioportal, GSCA, TIDE, and CellMiner CDB, plus molecular docking and siRNA knockdown experiments in paclitaxel-resistant cells.",{"name":119,"@type":110,"acceptedAnswer":120},"What key findings connect PTTG1 to immunotherapy and chemotherapy resistance?",{"text":121,"@type":113},"PTTG1 is overexpressed and generally predicts poor survival. High expression is linked to immune infiltration, immunotherapy resistance, T-cell exhaustion, cytotoxic T-lymphocyte dysfunction, and associations with sensitivity to multiple anticancer drugs.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},338383,1790441819,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":39,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},2336464648746,"https://ap-avatar.wpscdn.com/davatar_276721f389ce27ea32af1340a28f341c","Wei et al. BMC Cancer (2024) 24:1315 BMC Cancer  \n[https://doi.org/10.1186/s12885-024-13060-5](https://doi.org/10.1186/s12885-024-13060-5)  \nRESEARCH Open Access  \nMulti-omics analysis identifies PTTG1 as a prognostic biomarker associated with immunotherapy and chemotherapy resistance  \nHandong Wei 1, Yaxin Ma 1, Shuxing Chen 1, Chunlin Zou 1* and Lihui Wang 1*  \nAbstract  \nBackground Pituitary tumor-transforming gene 1 (PTTG1) is an important gene in tumour development. However, the relevance of PTTG1 in tumour prognosis, immunotherapy response, and medication sensitivity in human pancancer has to be determined.  \nMethods TIMER, GEPIA, the human protein atlas, GEPIA, TISCH2, and cBioportal examined the gene expression, protein expression, prognostic value, and genetic modification landscape of PTTG1 in 33 malignancies based on the TCGA cohort. The association between PTTG1 and tumour immunity, tumour microenvironment, immunotherapy response, and anticancer drug sensitivity was investigated using GSCA, TIDE, and CellMiner CDB. Molecular docking was used to validate the possible chemotherapeutic medicines for PTTG1 . Additionally, siRNA-mediated knockdown was employed to confirm the probable role of PTTG1 in paclitaxel-resistant cells.  \nResults PTTG1 is overexpressed and associated with poor survival in most tumors. Functional enrichment study revealed that PTTG1 is involved in the cell cycle and DNA replication. A substantial connection between PTTG1 expression and immune cell infiltration points to PTTG1’s possible role in the tumour microenvironment. High PTTG1 expression is associated with tumour immunotherapy resistance. The process could be connected to PTTG1, which mediatesT cell exhaustion and promotes cytotoxic T lymphocyte malfunction. Furthermore, PTTG1 was found to be substantially linked with sensitivity to several anticancer medications. Suppressing PTTG1 with siRNA reduced clone formation and migration, implying that PTTG1 may play a role in paclitaxel resistance.  \nConclusion PTTG1 shows potential as a cancer diagnostic, prognostic, and chemosensitivity marker. Increased PTTG1 expression is linked to resistance to cancer treatment. The mechanism could be linked to PTTG1’s role in promoting cytotoxic T lymphocyte dysfunction and mediating T cell exhaustion. It is feasible to consider PTTG1, which is expressed onTreg andTprol if cells, as a new therapeutic target for overcoming immunotherapy resistance.  \nHandong Wei andYaxin Ma are co-first authors.  \n*Correspondence:  \nChunlin Zou [zouchunlin@sohu.com](zouchunlin@sohu.com)[ ](zouchunlin@sohu.com)Lihui Wang [hellowanglihui@hotmail.com](hellowanglihui@hotmail.com)  \nFull list of author information is available at the end of the article  \n© The Author(s) 2024. Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit [http://](http://)[ ](http://)[creativecommons.org/l](creativecommons.org/l)icenses/by-nc-nd/4.0/.  \nWei et al. BMC Cancer (2024) 24:1315 Page 2 of 18  \nKeywords PTTG1, Tumor immunity, Immunotherapy, Drug sensitivity, Pan-cancer  \nIntroduction  \nThe pitui","cbCaikYRHFO8HOv7","https://ap.wps.com/l/cbCaikYRHFO8HOv7","pdf",13609164,18,"English","# Abstract\n## Background\n## Methods\n## Results\n## Conclusion\n# Introduction","[{\"question\":\"What is the research focus regarding PTTG1 in this study?\",\"answer\":\"The study examines how PTTG1 relates to tumor prognosis, immunotherapy response, and medication sensitivity across pan-cancer datasets.\"},{\"question\":\"Which analytical resources and approaches were used to study PTTG1?\",\"answer\":\"The work uses TIMER, GEPIA, Human Protein Atlas, TISCH2, cBioportal, GSCA, TIDE, and CellMiner CDB, plus molecular docking and siRNA knockdown experiments in paclitaxel-resistant cells.\"},{\"question\":\"What key findings connect PTTG1 to immunotherapy and chemotherapy resistance?\",\"answer\":\"PTTG1 is overexpressed and generally predicts poor survival. High expression is linked to immune infiltration, immunotherapy resistance, T-cell exhaustion, cytotoxic T-lymphocyte dysfunction, and associations with sensitivity to multiple anticancer drugs.\"}]","Multi-omics analysis identifies PTTG1 as a prognostic biomarker associated with immunotherapy and chemotherapy resistance | PDF",1790023377,45,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/9b20a70854ed93774a2a57b6fe9b4e50.webp",983,1310,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/e4b16e4ac82937bc3021ba58ea9a9941.webp",982,1309,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/3c3170c341add57bda020e42461bc155.webp",981,1308,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/319064cbe8d35a3975264b565ff6f7ff.webp",980,1306]